{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:39:25Z","timestamp":1791085165509,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05806-6","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:49:03Z","timestamp":1740379743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Very long-term remission in behcet\u2019s disease following withdrawal of anti-TNF treatment exceeds relapses: a reappraisal of an outcome study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-1518","authenticated-orcid":false,"given":"Aikaterini","family":"Arida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Markomichelakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"5806_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMRA2305712","volume":"390","author":"D Saadoun","year":"2024","unstructured":"Saadoun D, Bodaghi B, Cacoub P (2024) Beh\u00e7et\u2019s syndrome. N Engl J Med 390:640\u2013651. https:\/\/doi.org\/10.1056\/NEJMRA2305712","journal-title":"N Engl J Med"},{"key":"5806_CR2","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi G, Bettiol A, Hatemi G, Prisco D (2024) Beh\u00e7et\u2019s syndrome. Lancet (London England) 403:1093\u20131108. https:\/\/doi.org\/10.1016\/S0140-6736(23)02629-6","journal-title":"Lancet (London England)"},{"key":"5806_CR3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/ANNRHEUMDIS-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 77:808\u2013818. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2018-213225","journal-title":"Ann Rheum Dis"},{"key":"5806_CR4","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/RHEUMATOLOGY\/KEY242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler Y, Leccese P, Christensen R et al (2018) Management of major organ involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford) 57:2200\u20132212. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEY242","journal-title":"Rheumatology (Oxford)"},{"key":"5806_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/J.SEMARTHRIT.2018.05.008","volume":"48","author":"P Leccese","year":"2019","unstructured":"Leccese P, Ozguler Y, Christensen R et al (2019) Management of skin, mucosa and joint involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Semin Arthritis Rheum 48:752\u2013762. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2018.05.008","journal-title":"Semin Arthritis Rheum"},{"key":"5806_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 358:295\u2013296. https:\/\/doi.org\/10.1016\/S0140-6736(01)05497-6","journal-title":"Lancet"},{"key":"5806_CR7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/RHEUMATOLOGY\/KEM034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Beh\u00e7et\u2019s disease\u2014review and basis for recommendations. Rheumatology 46:736\u2013741. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEM034","journal-title":"Rheumatology"},{"key":"5806_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13075-018-1793-7\/TABLES\/5","volume":"21","author":"S Ohno","year":"2019","unstructured":"Ohno S, Umebayashi I, Matsukawa M et al (2019) Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther 21:1\u201312. https:\/\/doi.org\/10.1186\/S13075-018-1793-7\/TABLES\/5","journal-title":"Arthritis Res Ther"},{"key":"5806_CR9","doi-asserted-by":"publisher","unstructured":"Hatemi G, Tukek NB, Esatoglu SN et al (2023) Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome. Clin Immunol 253. https:\/\/doi.org\/10.1016\/J.CLIM.2023.109682","DOI":"10.1016\/J.CLIM.2023.109682"},{"key":"5806_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/S00296-022-05136-X","volume":"42","author":"G Evangelatos","year":"2022","unstructured":"Evangelatos G, Bamias G, Kitas GD et al (2022) The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 42:1493\u20131511. https:\/\/doi.org\/10.1007\/S00296-022-05136-X","journal-title":"Rheumatol Int"},{"key":"5806_CR11","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/art.40235","volume":"69","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Arida A, Panopoulos S et al (2017) Brief report: drug-free long-term remission in severe Beh\u00e7et\u2019s Disease following withdrawal of successful anti\u2013tumor necrosis factor treatment. Arthritis Rheumatol 69:2380\u20132385. https:\/\/doi.org\/10.1002\/art.40235","journal-title":"Arthritis Rheumatol"},{"key":"5806_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/0140-6736(90)92643-V","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Behcet\u2019s disease. Lancet 335:1078\u20131080. https:\/\/doi.org\/10.1016\/0140-6736(90)92643-V","journal-title":"Lancet"},{"key":"5806_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/RHEUMATOLOGY\/KEG453","volume":"43","author":"G Lawton","year":"2004","unstructured":"Lawton G, Bhakta BB, Chamberlain MA, Tennant A (2004) The Behcet\u2019s disease activity index. Rheumatology (Oxford) 43:73\u201378. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEG453","journal-title":"Rheumatology (Oxford)"},{"key":"5806_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09273948.2020.1774907","volume":"30","author":"HC K\u00f6se","year":"2022","unstructured":"K\u00f6se HC, Yal\u00e7\u0131nda\u011f N (2022) Clinical follow-up of patients with Beh\u00e7et Uveitis after Discontinuation of Infliximab Therapy. Ocul Immunol Inflamm 30:203\u2013207. https:\/\/doi.org\/10.1080\/09273948.2020.1774907","journal-title":"Ocul Immunol Inflamm"},{"key":"5806_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/J.CGH.2017.09.061","volume":"16","author":"C Reenaers","year":"2018","unstructured":"Reenaers C, Mary JY, Nachury M et al (2018) Outcomes 7 years after Infliximab Withdrawal for patients with Crohn\u2019s Disease in Sustained Remission. Clin Gastroenterol Hepatol 16:234\u2013243e2. https:\/\/doi.org\/10.1016\/J.CGH.2017.09.061","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5806_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ARD-2024-226113","author":"R Talarico","year":"2024","unstructured":"Talarico R, Italiano N, Emmi G et al (2024) Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ARD-2024-226113","journal-title":"Ann Rheum Dis"},{"key":"5806_CR17","doi-asserted-by":"publisher","unstructured":"Zhong Z, Deng D, Gao Y et al (2024) Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Beh\u00e7et\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial. https:\/\/doi.org\/10.1016\/S2665-9913(24)00194-2. Lancet Rheumatol 6:","DOI":"10.1016\/S2665-9913(24)00194-2"},{"key":"5806_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAE585","author":"RJ Moots","year":"2024","unstructured":"Moots RJ, Fortune F, Jackson R et al (2024) Infliximab versus interferon-alpha in the treatment of Beh\u00e7et\u2019s syndrome: clinical data from the BIO-BEH\u00c7ET\u2019S randomised controlled trial. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAE585","journal-title":"Rheumatology (Oxford)"},{"key":"5806_CR19","doi-asserted-by":"publisher","unstructured":"Saadoun D, Maalouf G, Vieira M et al (2024) Infliximab versus Cyclophosphamide for severe Beh\u00e7et\u2019s syndrome. NEJM Evid 3. https:\/\/doi.org\/10.1056\/EVIDOA2300354","DOI":"10.1056\/EVIDOA2300354"},{"key":"5806_CR20","first-page":"S86","volume":"35","author":"G Guzelant","year":"2017","unstructured":"Guzelant G, Ucar D, Esatoglu SN et al (2017) Infliximab for uveitis of Beh\u00e7et\u2019s syndrome: a trend for earlier initiation. Clin Exp Rheumatol 35:S86\u2013S89","journal-title":"Clin Exp Rheumatol"},{"key":"5806_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/S00296-017-3775-5","volume":"38","author":"J Sota","year":"2018","unstructured":"Sota J, Rigante D, Lopalco G et al (2018) Biological therapies for the treatment of Beh\u00e7et\u2019s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int 38:25\u201335. https:\/\/doi.org\/10.1007\/S00296-017-3775-5","journal-title":"Rheumatol Int"},{"key":"5806_CR22","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1093\/RHEUMATOLOGY\/KEAB944","volume":"61","author":"NB Tukek","year":"2022","unstructured":"Tukek NB, Esatoglu SN, Hatemi G et al (2022) Emergence of new manifestations during infliximab treatment in Beh\u00e7et\u2019s syndrome. Rheumatology (Oxford) 61:3746\u20133753. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAB944","journal-title":"Rheumatology (Oxford)"},{"key":"5806_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAE416","author":"SN Esatoglu","year":"2024","unstructured":"Esatoglu SN, Sonmez O, Ucar D et al (2024) De novo manifestations during adalimumab treatment in Beh\u00e7et\u2019s syndrome. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAE416","journal-title":"Rheumatology (Oxford)"},{"key":"5806_CR24","doi-asserted-by":"publisher","unstructured":"Fragoulis GE, Bertsias G, Bodaghi B et al (2023) Treat to target in Behcet\u2019s disease: should we follow the paradigm of other systemic rheumatic diseases? Clin Immunol 246. https:\/\/doi.org\/10.1016\/J.CLIM.2022.109186","DOI":"10.1016\/J.CLIM.2022.109186"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05806-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T15:13:38Z","timestamp":1742656418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["5806"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05806-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}